Jazz Pharmaceuticals, Inc. (JAZZ) Misses Q4 EPS by 6c, Offers Guidance
Tweet Send to a Friend
Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) reported Q4 EPS of $1.72, $0.06 worse than the analyst estimate ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
